ORBITA-CTO Trial: Evaluating the Impact of Percutaneous Coronary Intervention on Symptomatic Chronic Total Occlusion in Stable Angina

Highlight

• The ORBITA-CTO trial is the first placebo-controlled, randomized study assessing CTO PCI efficacy in stable angina patients with single-vessel coronary chronic total occlusion (CTO).
• CTO PCI significantly improved daily angina symptom burden, increasing angina-free days by over 30 days versus placebo at 6 months.
• Improvements were confirmed across patient-reported outcomes including the Seattle Angina Questionnaire and Canadian Cardiovascular Society class, with blinded assessment maintained.

Study Background